Epidemiology of Ulcerative Colitis in South Asia

Infliximab‐induced tuberculosis in patients with UC: Experience from India—a country with high prevalence of tuberculosis

“…The practice of administering Bacillus‐Calmette‐Guerin (BCG) at birth further complicates the issue of interpretation of tests for latent TB in such geographical areas. The current study was therefore undertaken to evaluate the magnitude of the problem of development of TB following IFX therapy in India, which has a high prevalence of TB and a moderately high prevalence of IBD as compared with the rest of Asia …”

“…The current study was therefore undertaken to evaluate the magnitude of the problem of development of TB following IFX therapy in India, which has a high prevalence of TB and a moderately high prevalence of IBD as compared with the rest of Asia. 6…”

Extent of disease is a major outcome predictor in patients with ulcerative colitis and pregnancy

“…On the contrary, the Indian subcontinent has the reverse situation of having a lower incidence of IBD vis-a-vis the West but a significantly higher birth rate of 20.2/1,000 population [6]. India has one of the highest prevalence rates of ulcerative colitis (UC) in Asia along with Japan and Korea [7]. These demographic data make it an important region to study the two-way interaction between IBD and pregnancy.…”

Fecal Microbial Transplant- A New Hope of Treatment for Ulcerative Colitis

“…5 Ulcerative colitis was first reported from India in the late 1930s. 6 Later on the existence of the disease was reported in the northern and western parts of the country. Amongst Asian countries, India has the highest incidence and prevalence of ulcerative colitis followed by Japan and Korea.…”

“…Amongst Asian countries, India has the highest incidence and prevalence of ulcerative colitis followed by Japan and Korea. 6 With the changing epidemiology of IBD, it is predicted that there will be an increase in IBD patients in Asia, Southern America as well as East Europe. 5 The high cost of second line drugs along with the need for life long therapy are the most distressing factors demanding the new innovative therapy for the treatment of the disease.…”